Topics:

FDA Accepts Satraplatin NDA and Grants Priority Review

FDA Accepts Satraplatin NDA and Grants Priority Review

Spectrum Pharmaceuticals, Inc, recently announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the US Food and Drug Administration (FDA). A Prescription Drug User Fee Act date of August 15, 2007, has been established by the FDA for a decision regarding the approval of the satraplatin application. Satraplatin is an investigational drug for the treatment of hormone-refractory prostate cancer in patients who have failed prior chemotherapy.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.